Clinical Trial

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The aim of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines CAR T cells and IgT cells to treat sarcoma.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2017-11-24; most recent amendment 2026-06-18.
Status change: Not Yet Recruiting → Recruiting 2017-12-03
Trial Details
NCT Number NCT03356782
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions Sarcoma, Osteoid Sarcoma, Ewing Sarcoma
Enrollment 20 participants
Start Date 2026-06-01
Primary Completion 2029-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-23